Chames Kermi

Investment Advantary and our capital partners are sector- and stage-agnostic investors using an SPV model that focuses on you and your company. We invest in revenue-generating companies at the pre-seed, seed, and growth rounds, as well as in traditional buyouts, management buyouts, and rollups where we believe our expertise can drive transformation that unlocks the potential of great companies. We are committed to a long-term investment approach. This allows us and our management teams to focus on the actions necessary to create, drive and maximize sustainable long-term value. Team and Services Our team of extraordinary operating partners and advisors have deep operating, execution, turnaround, and investment experience. We leverage these skills for our portfolio and for select non-portfolio companies.

Founded in 2014, we’re America’s largest venture firm for individual investors and VC investing partner to over 11,000 individuals and institutions. Offerings include institutional-grade funds with large diversified portfolios and deal-by-deal investing through our Syndicates. Investment minimum is $10,000. • Top-20 VC Firm (Time Magazine ’25) • Top-Decile Investment Performance (Carta Benchmarks ‘25) • Top 20 VC Firm (CB Insights 24) • Top 50 Unicorn VC (Stanford GSB Research ‘25) • Top 3 Most Active US VC Firm (PitchBook ‘18 - ‘24) • Most Founder Friendly Investor List (Inc. Magazine ‘24) • Worlds Most Innovative Companies (Fast Company 22) • #1 Most Active Venture Firm in the US (PitchBook 22 & 23) • Top 20 Venture Firm (CB Insights 24) • Worlds Most Innovative Companies (Fast Company 22) • Portfolio of 1,600+ current and historical companies • 40+ full-time VC investors • Founders get access to our community of 850,000+ members and 6,000+ Experts. Offers of securities made only to eligible investors by formal offering documents describing risks, terms, and other important information that must be considered before investing. Example portfolio companies shown for illustrative purposes only, do not necessarily reflect investment outcomes that were or would be obtained by any AV fund or investor, and are not available to future investors, except potentially in follow-on investments. Venture capital investing involves substantial risk, including risk of loss of all capital invested. Past performance does not guarantee future results. The content on this account is intended solely for persons located in the U.S. and is not directed at, and must not be acted upon, by any person in the United Kingdom. UK residents seeking information about AV should refer only to communications issued by Alumni Ventures UK LLP, which provides information solely on a non-promotional basis and only distributes Financial Promotions to eligible recipients in accordance with UK law.

"Timothy Witucki, Founder and CEO; is a seasoned entrepreneur, investor, and five-time founder, (5X)." We help startup’s and later-stage companies ($10M-$100M+ rounds) close capital raises, M&A deals, and NASDAQ IPOs across Southeast Asia, the US, and Europe. Heres how: We connect you with my global network of private investors, family offices, and institutional funds (from Chase to BlackRock) to secure the capital you need. Then I guide you through the entire process: from valuation and deal structuring to due diligence and closing. What you get: • No upfront fees (I take compensation on the back end after you close) • Pre-vetted investor interest before we even sign • White-glove advisory through M&A, SPACs, and IPO listings • Access to a 25-year network including billionaire investors and institutional funds Over 25 years, we have facilitated and invested in capital raises and structured deals ranging from $5M to $500M across North America, Southeast Asia (Singapore, Hong Kong, Manila, Malaysia, Indonesia), Europe, and the Middle East. We work with: → Stage 1-2-3 tech/AI companies raising $10M-$100M+ → Healthcare and life sciences companies pursuing growth capital → Commercial real estate developers and owners seeking both equity, debt and/or property acquisitions → Companies preparing for M&A, SPAC, or NASDAQ IPO → Founders tired of getting hit with massive upfront fees from banks We only take 3-5 exceptional deals per year. So if youre raising capital or planning an exit, DM me. Otherwise, hope you get value from my content. Timothy Timothy@Wituckicapital.com

We bridge the gap between visionary angel investors and the next generation of groundbreaking startups, especially in high-impact sectors like biotech, digital health, and regenerative medicine. Securing early-stage funding is just the beginning. We’ll uncover the critical factor that determines whether investors back a biotech startup or pass. ✔ Expert VC & Angel Fundraising – From pitch decks to investor matchmaking, we prepare you for success. ✔ Deep Biotech & Health Tech Focus – We evaluate scientific feasibility, market potential, and competitive positioning so you stand out. ✔ Data-Driven Due Diligence – Our team assesses commercialization risks, business models, and financial viability—before you pitch. ✔ Strategic Growth Roadmaps – We refine go-to-market strategies, funding plans, and investor materials (decks, business plans, financial models).

We’re celebrating over 175 years of daring scientific innovation—and we’re not done yet. Let’s outdo yesterday. Protect your health at PfizerForAll.com For additional information on our guidelines, please visit http://www.pfizer.com/community-guidelines